ライフサイエンスコーパス: we enrolled

1 We enrolled 10 SCA38 patients, and carried out a double-blind

2 We enrolled 11 severely obese and 12 nonobese patients and ob

3 Between Jan 16, 2007, and Dec 17, 2013, we enrolled 12 patients who were randomly assigned either to

4 We enrolled 1278 cases and 2343 controls.

5 We enrolled 18 consecutive patients meeting study criteria sc

6 Between Oct 14, 2013, and Oct 17, 2014, we enrolled 2018 caregivers and their infants from 152 villag

7 METHODS AND We enrolled 2149 adults aged 25 to 41 years from the general

8 Between Feb 1, 2013, and Aug 31, 2014, we enrolled 228 patients with first-episode psychosis and 105

9 We enrolled 26 participants and tested 130 seminal fluid spec

10 We enrolled 30 patients with mild-to-moderate AD in a randomi

11 We enrolled 32 men with BCR of PCa, who were 59-83 y old (mea

12 From 2000-2012, we enrolled 32,875 patients in California with active TB and

13 METHODS AND We enrolled 335 consecutive valvular heart disease subjects w

14 Between Aug 1, 2015, and Jan 29, 2016, we enrolled 345 eligible transwomen.

15 Between Dec 29, 2014, and May 3, 2016, we enrolled 35 patients, of whom 32 (91%) underwent randomisa

16 Between Feb 2, 2015, and April 24, 2015, we enrolled 351 patients, with 211 (60%) randomly assigned (1

17 We enrolled 4,556 infants that were at least 2,000 g at birth

18 We enrolled 40 children aged 9 to 36 months with suspected or

19 We enrolled 4093 postmenopausal women with osteoporosis and a

20 Between April 6, 2009, and Jan 3, 2012, we enrolled 452 patients (225 [50%] in the two chemotherapy-a

21 We enrolled 5823 patients within 1 year (with 98% follow-up).

22 We enrolled 786 505 (64.2%) were adults and 281 (35.8%) were

23 We enrolled 821 patients with a median (interquartile range)

24 Between Jan 18 and Feb 24, 2014, we enrolled 93 participants into the main study cohort with 4

25 We enrolled 94 subjects who were microbiologically classified

26 We enrolled 953 matched controls, including 683 matched to P

27 We enrolled a convenience sample of 220 adult male survivors

28 We enrolled adult patients (aged >/=18 years) who had cytolog

29 tional, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-positive mycosis fungoid

30 For this prospective study, we enrolled adults (aged >/=18 years) living with HIV with CD

31 In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged >/=18 years) with histologically con

32 Between Oct 28, 2013, and July 29, 2015, we enrolled and randomly allocated 377 participants (188 [50%

33 Between May 7, 2013, and March 25, 2014, we enrolled and randomly assigned 365 patients to different t

34 Between Oct 21, 2013, and Jan 11, 2016, we enrolled and vaccinated 101 participants with 306 doses of

35 We enrolled cases with microscopy-positive, PCR-confirmed mal

36 We enrolled eligible cases declared to the National Reference

37 In this case-control study, we enrolled febrile patients presenting to outpatient departm

38 In stage 2 of the study (reported here), we enrolled healthy adolescents who had received three doses

39 bel trial conducted in Uganda, Zimbabwe, Malawi, and Kenya, we enrolled HIV-infected adults and children 5 years of age o

40 rchases.In this parallel-group randomized controlled trial, we enrolled household shoppers across New Zealand who owned s

41 For this prospective cohort study, we enrolled male patients aged 2-28 years with Duchenne muscu

42 We enrolled men and postmenopausal or hysterectomised women (

43 We enrolled patients 6 months of age or older who presented w

44 We enrolled patients aged 18 years or older with HCV genotype

45 In this observational cohort study, we enrolled patients with idiopathic or heritable pulmonary a

46 We enrolled patients with primary refractory or relapsed myel

47 We enrolled postmenopausal women of any age with hormone rece

48 In this double-blind randomised placebo-controlled trial, we enrolled undiagnosed patients, aged 18-80 years, with coug

49 In this single-arm, open-label trial, we enrolled virologically suppressed, HIV-infected children f

50 We enrolled young infants (aged 0-59 days) who either present